189 related articles for article (PubMed ID: 27041577)
1. CD146 is a novel marker for highly tumorigenic cells and a potential therapeutic target in malignant rhabdoid tumor.
Nodomi S; Umeda K; Saida S; Kinehara T; Hamabata T; Daifu T; Kato I; Hiramatsu H; Watanabe KI; Kuwahara Y; Iehara T; Adachi S; Konishi E; Nakahata T; Hosoi H; Heike T
Oncogene; 2016 Oct; 35(40):5317-5327. PubMed ID: 27041577
[TBL] [Abstract][Full Text] [Related]
2. CD146 is a potential immunotarget for neuroblastoma.
Obu S; Umeda K; Ueno H; Sonoda M; Tasaka K; Ogata H; Kouzuki K; Nodomi S; Saida S; Kato I; Hiramatsu H; Okamoto T; Ogawa E; Okajima H; Morita K; Kamikubo Y; Kawaguchi K; Watanabe K; Iwafuchi H; Yagyu S; Iehara T; Hosoi H; Nakahata T; Adachi S; Uemoto S; Heike T; Takita J
Cancer Sci; 2021 Nov; 112(11):4617-4626. PubMed ID: 34464480
[TBL] [Abstract][Full Text] [Related]
3. Novel Two MRT Cell Lines Established from Multiple Sites of a Synchronous MRT Patient.
Kuwahara Y; Iehara T; Ichise E; Katsumi Y; Ouchi K; Tsuchiya K; Miyachi M; Konishi E; Sasajima H; Nakamura S; Fumino S; Tajiri T; Johann PD; FrÜhwald MC; Yoshida T; Okuda T; Hosoi H
Anticancer Res; 2020 Nov; 40(11):6159-6170. PubMed ID: 33109553
[TBL] [Abstract][Full Text] [Related]
4. Somatic mutations and single-cell transcriptomes reveal the root of malignant rhabdoid tumours.
Custers L; Khabirova E; Coorens THH; Oliver TRW; Calandrini C; Young MD; Vieira Braga FA; Ellis P; Mamanova L; Segers H; Maat A; Kool M; Hoving EW; van den Heuvel-Eibrink MM; Nicholson J; Straathof K; Hook L; de Krijger RR; Trayers C; Allinson K; Behjati S; Drost J
Nat Commun; 2021 Mar; 12(1):1407. PubMed ID: 33658498
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of gefitinib in malignant rhabdoid tumor cells in vitro and in vivo.
Kuwahara Y; Hosoi H; Osone S; Kita M; Iehara T; Kuroda H; Sugimoto T
Clin Cancer Res; 2004 Sep; 10(17):5940-8. PubMed ID: 15355927
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a pineal region malignant rhabdoid tumor. Towards understanding brain tumor cell invasion.
Muller M; Hubbard SL; Fukuyama K; Dirks P; Matsuzawa K; Rutka JT
Pediatr Neurosurg; 1995; 22(4):204-9. PubMed ID: 7619721
[TBL] [Abstract][Full Text] [Related]
7. Identification of CD146 as a marker enriched for tumor-propagating capacity reveals targetable pathways in primary human sarcoma.
Wei Q; Tang YJ; Voisin V; Sato S; Hirata M; Whetstone H; Han I; Ailles L; Bader GD; Wunder J; Alman BA
Oncotarget; 2015 Nov; 6(37):40283-94. PubMed ID: 26517673
[TBL] [Abstract][Full Text] [Related]
8. [Studies of the origin of malignant rhabdoid tumor(MRT)--experimental researches on the MRT evolving in nude mice inoculated with violently variable HeLa cells].
Zhang DL; Huang GS; Li LJ; He XY; Xia GT; Gao BX; Bai XH; Liu SG
Yi Chuan Xue Bao; 2000; 27(12):1057-71. PubMed ID: 11209698
[TBL] [Abstract][Full Text] [Related]
9. Extrarenal rhabdoid tumors of soft tissue: clinicopathological and molecular genetic review and distinction from other soft-tissue sarcomas with rhabdoid features.
Oda Y; Tsuneyoshi M
Pathol Int; 2006 Jun; 56(6):287-95. PubMed ID: 16704491
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor 2 axis supports the serum-independent growth of malignant rhabdoid tumor and is activated by microenvironment stress.
Li T; Wang J; Liu P; Chi J; Yan H; Lei L; Li Z; Yang B; Wang X
Oncotarget; 2017 Jul; 8(29):47269-47283. PubMed ID: 28521298
[TBL] [Abstract][Full Text] [Related]
11. Malignant rhabdoid tumor shows incomplete neural characteristics as revealed by expression of SNARE complex.
Yoshida S; Narita T; Taga T; Ohta S; Takeuchi Y
J Neurosci Res; 2002 Sep; 69(5):642-52. PubMed ID: 12210830
[TBL] [Abstract][Full Text] [Related]
12. In Vivo Expansion of Cancer Stemness Affords Novel Cancer Stem Cell Targets: Malignant Rhabdoid Tumor as an Example.
Golan H; Shukrun R; Caspi R; Vax E; Pode-Shakked N; Goldberg S; Pleniceanu O; Bar-Lev DD; Mark-Danieli M; Pri-Chen S; Jacob-Hirsch J; Kanter I; Trink A; Schiby G; Bilik R; Kalisky T; Harari-Steinberg O; Toren A; Dekel B
Stem Cell Reports; 2018 Sep; 11(3):795-810. PubMed ID: 30122444
[TBL] [Abstract][Full Text] [Related]
13. Suppression of malignant rhabdoid tumors through Chb-M'-mediated RUNX1 inhibition.
Daifu T; Mikami M; Hiramatsu H; Iwai A; Umeda K; Noura M; Kubota H; Masuda T; Furuichi K; Takasaki S; Noguchi Y; Morita K; Bando T; Hirata M; Kataoka TR; Nakahata T; Kuwahara Y; Iehara T; Hosoi H; Takita J; Sugiyama H; Adachi S; Kamikubo Y
Pediatr Blood Cancer; 2021 Feb; 68(2):e28789. PubMed ID: 33180377
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of miRNAs in rhabdomyosarcoma and malignant rhabdoid tumor.
Armeanu-Ebinger S; Herrmann D; Bonin M; Leuschner I; Warmann SW; Fuchs J; Seitz G
Exp Cell Res; 2012 Dec; 318(20):2567-77. PubMed ID: 23000453
[TBL] [Abstract][Full Text] [Related]
15. INI1 expression induces cell cycle arrest and markers of senescence in malignant rhabdoid tumor cells.
Reincke BS; Rosson GB; Oswald BW; Wright CF
J Cell Physiol; 2003 Mar; 194(3):303-13. PubMed ID: 12548550
[TBL] [Abstract][Full Text] [Related]
16. Expression of neural stem cell markers in malignant rhabdoid tumor cell lines.
Okuno K; Ohta S; Kato H; Taga T; Sugita K; Takeuchi Y
Oncol Rep; 2010 Feb; 23(2):485-92. PubMed ID: 20043111
[TBL] [Abstract][Full Text] [Related]
17. Pediatric extra-renal rhabdoid tumors with unusual morphology: a diagnostic pitfall for small biopsies.
Alaggio R; Boldrini R; Di Venosa B; Rosolen A; Bisogno G; Magro G
Pathol Res Pract; 2009; 205(7):451-7. PubMed ID: 19243895
[TBL] [Abstract][Full Text] [Related]
18. Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1/Snf5-mediated tumorigenesis.
Darr J; Klochendler A; Isaac S; Eden A
Oncogene; 2014 Jun; 33(23):3024-32. PubMed ID: 23851500
[TBL] [Abstract][Full Text] [Related]
19. Malignant rhabdoid-tumor cell line showing neural and smooth-muscle-cell phenotypes.
Sugimoto T; Hosoi H; Horii Y; Ishida H; Mine H; Takahashi K; Abe T; Ohta S; Sawada T
Int J Cancer; 1999 Aug; 82(5):678-86. PubMed ID: 10417765
[TBL] [Abstract][Full Text] [Related]
20. A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain.
Sredni ST; Suzuki M; Yang JP; Topczewski J; Bailey AW; Gokirmak T; Gross JN; de Andrade A; Kondo A; Piper DR; Tomita T
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28398638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
